A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091

• Status: Recruiting
• Trial end date: 2021-12-26
• Target enrollment: 0
• Participant gender: Male

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109 in healthy male subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Addpharma Inc.
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit

• The Age equal to or greater than 19 in healthy male volunteers at the time of screening visit

Exclusion Criteria:

• Patients with Medical history increasing the risk of bleeding